Biomarkers in prostate cancer management. Is there something new?

CONCLUSIONS: The use of genetic PCa biomarkers has a unique role in screening, diagnosis, surveillance, risk stratification and treatment for this disease. It is important that providers be able to recommend the appropriatetest for each individual patient and circumstance within the disease. In the present time, no biomarker can be recommended over another, and large-scale and multi-institutional studies are required to validate the efficacy and cost utility of these new technologies. PMID: 30855011 [PubMed - in process]
Source: Archivos Espanoles de Urologia - Category: Urology & Nephrology Tags: Arch Esp Urol Source Type: research